467 related articles for article (PubMed ID: 25703885)
1. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
3. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
4. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
5. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
[TBL] [Abstract][Full Text] [Related]
6. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
7. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
[TBL] [Abstract][Full Text] [Related]
8. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
[TBL] [Abstract][Full Text] [Related]
9. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
[TBL] [Abstract][Full Text] [Related]
10. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
[TBL] [Abstract][Full Text] [Related]
11. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
[TBL] [Abstract][Full Text] [Related]
12. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
14. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
[TBL] [Abstract][Full Text] [Related]
15. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
[TBL] [Abstract][Full Text] [Related]
16. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW
JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190
[TBL] [Abstract][Full Text] [Related]
18. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Harada Y; Michel J; Lohaus R; Mayer K; Emmer R; Lahmann AL; Colleran R; Giacoppo D; Wolk A; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tölg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Wöhrle J; Kufner S; Morath T; Ibrahim T; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Mehilli J; Byrne RA; Kastrati A; Schulz-Schüpke S
Thromb Haemost; 2017 Oct; 117(10):1989-1999. PubMed ID: 28783201
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
20. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]